Famitinib
Famitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and mast/stem cell growth factor receptor Kit.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | C80 | 6 | 4 | — | — | — | 9 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 5 | — | — | — | 6 |
| Triple negative breast neoplasms | D064726 | — | 4 | — | — | — | 4 | ||
| Renal cell carcinoma | D002292 | — | 3 | — | — | — | 3 | ||
| Nasopharyngeal neoplasms | D009303 | 1 | 2 | — | — | — | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | 1 | — | — | — | 1 |
| Esophageal squamous cell carcinoma | D000077277 | — | 1 | — | — | — | 1 | ||
| Cholangiocarcinoma | D018281 | C22.1 | — | 1 | — | — | — | 1 | |
| Urologic neoplasms | D014571 | C64-C68 | — | 1 | — | — | — | 1 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 3 | — | — | — | — | 3 | ||
| Nasopharyngeal carcinoma | D000077274 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | FAMITINIB |
| INN | famitinib |
| Description | Famitinib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against platelet-derived growth factor receptor beta, vascular endothelial growth factor receptor 2, and mast/stem cell growth factor receptor Kit. |
| Classification | Small molecule |
| Drug class | tyrosine kinase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCN(CC)CCN1CCc2[nH]c(/C=C3\C(=O)Nc4ccc(F)cc43)c(C)c2C1=O |
Identifiers
| PDB | — |
| CAS-ID | 1044040-56-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1278146 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 768FW21J3L (ChemIDplus, GSRS) |
Target
Agency Approved
PDGFRB
PDGFRB
KDR
KDR
KIT
KIT
Organism
Homo sapiens
Gene name
PDGFRB
Gene synonyms
PDGFR, PDGFR1
NCBI Gene ID
Protein name
platelet-derived growth factor receptor beta
Protein synonyms
Activated tyrosine kinase PDGFRB, Beta platelet-derived growth factor receptor, Beta-type platelet-derived growth factor receptor, CD140 antigen-like family member B, CD140b, NDEL1-PDGFRB, PDGF-R-beta, PDGFR-1, PDGFR-beta, Platelet-derived growth factor receptor 1, platelet-derived growth factor receptor, beta polypeptide
Uniprot ID
Mouse ortholog
Pdgfrb (18596)
platelet-derived growth factor receptor beta (P05622)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 181 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more